

中国肿瘤生物治疗杂志

CHINESE J 0 |



首页 期刊概况 编委会 期刊内容 特邀审稿 投稿指南 出版发行

505~509.异种EGFR口服DNA疫苗抑制小鼠Lewis肺癌的生长[J].武建毅,刘 岽,唐 亮,谈立松,黄晓东.中国肿瘤生物治疗杂志,2010,17(5)

异种EGFR口服DNA疫苗抑制小鼠Lewis肺癌的生长 点此下载全文

武建毅 刘 岽 唐 亮 谈立松 黄晓东

上海市普陀区人民医院 肿瘤科,上海 200060; 同济大学附属肺科医院 肺癌免疫研究室, 上海 200433; 同济大学附属肺科医院 肺癌免疫研究室, 上海 200433; 同济大学附属肺科医院 肺癌免疫研究室, 上海 200433; 同济大学附属肺科医院 肺癌免疫研究室, 上海 200433

基金项目: 上海市科委基金资助项目(No. 03DZ19263); 上海市普陀区卫生局资助项目(No. PTW08-Z01)

DOI:

摘要:

目的:观察表达异种鸡EGFR(chicren EGFR, cEGFR)与 IgGyFc融合基因的口服减毒鼠伤寒沙门菌疫苗对高表达EGFR 的肺癌Lewis细胞小鼠移植瘤生长的抑制作用。方法:将pVAX1-cEGFR-yFc质粒转化减毒沙门菌SL7207,重组菌SL7207/pVAX1-cEGFR-yFc体外感染小鼠腹腔巨噬细胞,免疫荧光法检测cEGFR-yFc融合蛋白的表达。SL7207/pVAX1-cEGFR-yFc重组菌口服免疫小鼠3次后接种Lewis细胞,Western blotting检测小鼠体内融合蛋白的表达,ELISA法检测免疫小鼠血清抗EGFR抗体的水平。接种Lewis细胞14 d后处死小鼠,瘤体称质量,检测SL7207/pVAX1-cEGFR-yFc疫苗对Lewis肺癌生长的抑制作用,测定荷瘤小鼠的生存时间。结果:成功构建减毒沙门菌疫苗SL7207/pVAX1-cEGFR-yFc,SL7207/pVAX1-cEGFR-yFc感染后,在小鼠后体内外都能检测到cEGFR-yFc融合蛋白的表达;SL7207/pVAX1-cEGFR-yFc疫苗口服免疫后小鼠能够产生高水平的抗EGFR抗体,口服SL7207/pVAX1-cEGFR-yFc疫苗能够有效抑制小鼠Lewis移植瘤的生长,延长荷瘤小鼠的生存时间。结论:异种EGFR口服DNA疫苗能够有效地抑制高表达EGFR肺癌的生长,是EGFR分子靶向治疗的一条新途径。

关键词:减毒沙门氏菌 表皮生长因子受体 肺肿瘤 DNA疫苗 异种同源抗原

Oral DNA vaccine expressing xenogeneic EGFR inhibits growth of Lewis lung cancer in mice Download Fulltext

WU Jian-yi LIU Dong TANG Liang TAN Li-song HUANG Xiao-dong

Department of Oncology, Putuo District People's Hospital of Shanghai, Shanghai 200060, China; Immunology Institute of Lung Cancer, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China; Immunology Institute of Lung Cancer, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China; Immunology Institute of Lung Cancer, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China; Immunology Institute of Lung Cancer, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China

Fund Project: Project supported by the Foundation of Shanghai Science Committee (No. 03DZ19263), and the Foundation of Health Bureau of Putuo District in Shanghai (No.PTW08-Z01)

Abstract:

Objective: To investigate the inhibitory effect of attenuated salmonella typhimurium vaccine, which expressing xenogeneic chicken EGFR and IgG yFc, on the growth of Lewis lung cancer (expressed high level of EGFR)-implanted tumors in mice. Methods: pVAX1/ cEGFR-yFc plasmid was transformed into attenuated salmonella typhimurium strain SL7207, and the resultant SL7207/pVAX1-cEGFR-yFc bacteria were used to infect murine peripheral macrophage in vitro. Then expression of cEGFR-yFc fusion protein was detected by immunofluorescent assay. Mice were immunized with SL7207/pVAX1-cEGFR-yFc for 3 times, and then inoculated with Lewis cells. Expression of cEGFR-yFc fusion protein in mice tissue was detected by Western blotting analysis, and serum anti-EGFR level was determined by ELISA method. The weight of implanted Lewis tumor was measured after 14 d to investigate the anti-tumor effect of SL7207/pVAX1-cEGFR-yFc vaccine, and the survival time of tumor-bearing mice was also examined. Results: The attenuated salmonella typhimurium DNA vaccine SL7207/pVAX1-cEGFR-yFc was successfully constructed. The cEGFR-yFc fusion protein could be expressed in mouse cells after SL7207/pVAX1-cEGFR-yFc infection in vitro and in vivo. The mice immunized with SL7207/pVAX1-cEGFR-yFc could produce high level of anti-EGFR antibody. The tumor growth was obviously inhibited and the survival time of tumor-bearing mice was also increased in the SL7207/pVAX1-cEGFR-yFc vaccine group. Conclusion: The DNA vaccine expressing xenogeneic EGFR can effectively inhibit the growth of EGFR-positive tumors, which is a new EGFR-targeting therapy strategy.

Keywords: attenuated salmonella typhimurium epidermal growth factor receptor lung neoplasmas DNA vaccine xenogeneic homologous antigen

查看全文 查看/发表评论 下载PDF阅读器

Copyright © Biother.Org™ All Rights Reserved 主管单位:中国科学技术协会 主办单位:中国免疫学会、中国抗癌学会地址:上海市杨浦区翔殷路800号 邮政编码: 200433 京ICP备06011393号-2本系统由北京勤云科技发展有限公司设计